Amarantus Announces Publication in BRAIN of Eltopr
Post# of 30028
Posted On: 02/10/2015 6:12:50 AM
Amarantus Announces Publication in BRAIN of Eltoprazine Phase 2a Clinical Study for Treating Parkinson's Disease Levodopa-Induced Dyskinesia
Download PDF
Eltoprazine demonstrated significant beneficial anti-dyskinesia effect at 5 and 7.5 mg doses, with no reduction of levodopa efficacy
Eltoprazine was well tolerated at all dose levels, with no major adverse effects reported
Results support advancing eltoprazine into Phase 2b chronic dosing, clinical studies, as a treatment for patients with Parkinson's disease levodopa-induced dyskinesia
SAN FRANCISCO and GENEVA, Feb. 10, 2015 (GLOBE NEWSWIRE) -- Amarantus BioSciences Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on developing diagnostics in neurology, and therapeutic products with the potential for orphan drug designation in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, announced that the publication of the results of a Phase 2a study of eltoprazine in Parkinson's disease levodopa-induced dyskinesias (PD-LID). The paper titled, "Eltoprazine Counteracts L-DOPA-induced Dyskinesias in Parkinson's Disease: A Dose-Finding Study," has been published in Oxford Journals (Oxford University Press) online and will appear shortly in a future print edition of BRAIN - A Journal of Neurology.
Eltoprazine is a small-molecule 5-HT1A/1B serotonin receptor agonist, investigational drug candidate, with a well-established safety profile. A Phase 2a dose-finding study was conducted with eltoprazine to determine its effect against levodopa-induced dyskinesia, in patients with Parkinson's disease (PD). The double-blind, randomized, placebo-controlled clinical study was led by Professor Per Svenningsson, M.D., Ph.D., Centre for Molecular Medicine, Karolinska Institutet, Professor Anders Björklund, Ph.D., Faculty of Medicine at Lund University, and Professor Håkan Widner, M.D., Ph.D., Faculty of Medicine at Lund University. The study was partially supported by a grant from The Michael J. Fox Foundation for Parkinson's Research.
Some researchers believe that, in the advanced stages of PD, as dopamine nerve terminals are lost, serotonergic terminals take up levodopa and convert it to dopamine instead. Unlike in dopamine nerve endings, the serotonin nerve terminals do not have a negative feedback loop, possibly causing an excessive release of dopamine and resulting in the development of abnormal involuntary hyperkinetic movements, known as levodopa-induced dyskinesias (LID). Pre-synaptic activation of serotonin receptors using a 5HT1A/1B agonist may dampen this excessive dopamine release. In animal model studies of LID previously conducted in Professor Björklund's laboratory, simultaneous activation of 5-HT1A and 5-HT1B receptors was shown to effectively block LID. The Phase 2a dosing trial with eltoprazine was conducted as an initial clinical pharmacology study to determine if activation of 5-HT1A/1B receptors in Parkinson's disease subjects may replicate the effects of serotonin receptor activation seen in pre-clinical dyskinesia studies.
The study in 22 subjects with long standing PD-LID was a randomized, four-way crossover design in which patients received a single dose of placebo and eltoprazine, at 2.5, 5 and 7.5 mg, in combination with a challenge dose of levodopa (1.5 times usual dose), on four different days, separated by an interval of a week. Data from the study demonstrated that eltoprazine significantly reduced peak dose dyskinesia at both the 5 and 7.5 mg doses using the Combined Dyskinesia Rating Scale. The 5 mg dose also showed a significant anti-dyskinetic effect on other measures of dyskinesia, including the Rush dyskinesia rating scale. Importantly, there were no adverse effects on levodopa efficacy at any dose level as evidenced by United Parkinson's Disease Rating Scale (UPDRS Part III) observation. Additionally, all dose levels of eltoprazine were well tolerated with no major adverse effects reported.
"Eltoprazine's anti-dyskinetic effect is promising, especially given the reduction in dyskinesia following a levodopa challenge at one and a half times greater than the regular levodopa dose," said Charlotte Keywood, M.D., Chief Medical Officer at Amarantus. "Levodopa treatment is the current standard of care for patients to manage PD motor symptoms, despite the occurrence of dyskinesia with long-term use. Thus, we were very pleased to see that normal motor responses to levodopa, measured by UPDRS III, remained unchanged in all patients treated with eltoprazine."
The Phase 2a study also included a pharmacokinetic (PK) evaluation of eltoprazine. The data show that the PK characteristics of eltoprazine in PD patients are the same as those found in healthy subjects. Given the positive PK profile in PD patients and the acute anti-dyskinesia effect seen with the 5 and 7.5 mg doses, further advancement of eltoprazine into Phase 2b chronic dosing clinical studies to treat patients with PD-LID is warranted.
"We are pleased to have the eltoprazine study results published in this prestigious peer-reviewed journal," said Dr. Keywood. "The results of this proof of concept, first trial in PD-LID patients, support the findings of the non-clinical pharmacology studies conducted using animal models of PD-LID and show the predictive value of these models in aiding human drug development."
"The data from this study show an acute antidyskinetic effect of eltoprazine with no detriment to levodopa efficacy. With these data at hand, we are confident moving forward into longer-term dosing studies to further evaluate the utility of eltoprazine as a treatment for levodopa-induced dyskinesia," concluded Dr. Keywood.
Amarantus expects to file its Investigational New Drug Application (IND) with the U.S. Food and Drug Administration (FDA) and commence its Phase 2b study of eltoprazine in PD-LID subjects in the first quarter of 2015.
"Dyskinesia impacts quality of life of people with Parkinson's disease, and is therefore a top priority for the Foundation," commented Maurizio Facheris, M.D., M.Sc., Associate Director of research programs at The Michael J. Fox Foundation. "We are glad to see this project moving further through clinical testing and closer to patients' hands."
To access the online version of the paper titled, "Eltoprazine Counteracts L-DOPA-induced Dyskinesias in Parkinson's Disease: A Dose-Finding Study," please click here.
To access the Karolinska Institutet press release titled, "New therapeutic principle for Parkinsonian dyskinesia shows clinical effect," regarding the publication in BRAIN, please click here.
Download PDF
Eltoprazine demonstrated significant beneficial anti-dyskinesia effect at 5 and 7.5 mg doses, with no reduction of levodopa efficacy
Eltoprazine was well tolerated at all dose levels, with no major adverse effects reported
Results support advancing eltoprazine into Phase 2b chronic dosing, clinical studies, as a treatment for patients with Parkinson's disease levodopa-induced dyskinesia
SAN FRANCISCO and GENEVA, Feb. 10, 2015 (GLOBE NEWSWIRE) -- Amarantus BioSciences Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on developing diagnostics in neurology, and therapeutic products with the potential for orphan drug designation in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, announced that the publication of the results of a Phase 2a study of eltoprazine in Parkinson's disease levodopa-induced dyskinesias (PD-LID). The paper titled, "Eltoprazine Counteracts L-DOPA-induced Dyskinesias in Parkinson's Disease: A Dose-Finding Study," has been published in Oxford Journals (Oxford University Press) online and will appear shortly in a future print edition of BRAIN - A Journal of Neurology.
Eltoprazine is a small-molecule 5-HT1A/1B serotonin receptor agonist, investigational drug candidate, with a well-established safety profile. A Phase 2a dose-finding study was conducted with eltoprazine to determine its effect against levodopa-induced dyskinesia, in patients with Parkinson's disease (PD). The double-blind, randomized, placebo-controlled clinical study was led by Professor Per Svenningsson, M.D., Ph.D., Centre for Molecular Medicine, Karolinska Institutet, Professor Anders Björklund, Ph.D., Faculty of Medicine at Lund University, and Professor Håkan Widner, M.D., Ph.D., Faculty of Medicine at Lund University. The study was partially supported by a grant from The Michael J. Fox Foundation for Parkinson's Research.
Some researchers believe that, in the advanced stages of PD, as dopamine nerve terminals are lost, serotonergic terminals take up levodopa and convert it to dopamine instead. Unlike in dopamine nerve endings, the serotonin nerve terminals do not have a negative feedback loop, possibly causing an excessive release of dopamine and resulting in the development of abnormal involuntary hyperkinetic movements, known as levodopa-induced dyskinesias (LID). Pre-synaptic activation of serotonin receptors using a 5HT1A/1B agonist may dampen this excessive dopamine release. In animal model studies of LID previously conducted in Professor Björklund's laboratory, simultaneous activation of 5-HT1A and 5-HT1B receptors was shown to effectively block LID. The Phase 2a dosing trial with eltoprazine was conducted as an initial clinical pharmacology study to determine if activation of 5-HT1A/1B receptors in Parkinson's disease subjects may replicate the effects of serotonin receptor activation seen in pre-clinical dyskinesia studies.
The study in 22 subjects with long standing PD-LID was a randomized, four-way crossover design in which patients received a single dose of placebo and eltoprazine, at 2.5, 5 and 7.5 mg, in combination with a challenge dose of levodopa (1.5 times usual dose), on four different days, separated by an interval of a week. Data from the study demonstrated that eltoprazine significantly reduced peak dose dyskinesia at both the 5 and 7.5 mg doses using the Combined Dyskinesia Rating Scale. The 5 mg dose also showed a significant anti-dyskinetic effect on other measures of dyskinesia, including the Rush dyskinesia rating scale. Importantly, there were no adverse effects on levodopa efficacy at any dose level as evidenced by United Parkinson's Disease Rating Scale (UPDRS Part III) observation. Additionally, all dose levels of eltoprazine were well tolerated with no major adverse effects reported.
"Eltoprazine's anti-dyskinetic effect is promising, especially given the reduction in dyskinesia following a levodopa challenge at one and a half times greater than the regular levodopa dose," said Charlotte Keywood, M.D., Chief Medical Officer at Amarantus. "Levodopa treatment is the current standard of care for patients to manage PD motor symptoms, despite the occurrence of dyskinesia with long-term use. Thus, we were very pleased to see that normal motor responses to levodopa, measured by UPDRS III, remained unchanged in all patients treated with eltoprazine."
The Phase 2a study also included a pharmacokinetic (PK) evaluation of eltoprazine. The data show that the PK characteristics of eltoprazine in PD patients are the same as those found in healthy subjects. Given the positive PK profile in PD patients and the acute anti-dyskinesia effect seen with the 5 and 7.5 mg doses, further advancement of eltoprazine into Phase 2b chronic dosing clinical studies to treat patients with PD-LID is warranted.
"We are pleased to have the eltoprazine study results published in this prestigious peer-reviewed journal," said Dr. Keywood. "The results of this proof of concept, first trial in PD-LID patients, support the findings of the non-clinical pharmacology studies conducted using animal models of PD-LID and show the predictive value of these models in aiding human drug development."
"The data from this study show an acute antidyskinetic effect of eltoprazine with no detriment to levodopa efficacy. With these data at hand, we are confident moving forward into longer-term dosing studies to further evaluate the utility of eltoprazine as a treatment for levodopa-induced dyskinesia," concluded Dr. Keywood.
Amarantus expects to file its Investigational New Drug Application (IND) with the U.S. Food and Drug Administration (FDA) and commence its Phase 2b study of eltoprazine in PD-LID subjects in the first quarter of 2015.
"Dyskinesia impacts quality of life of people with Parkinson's disease, and is therefore a top priority for the Foundation," commented Maurizio Facheris, M.D., M.Sc., Associate Director of research programs at The Michael J. Fox Foundation. "We are glad to see this project moving further through clinical testing and closer to patients' hands."
To access the online version of the paper titled, "Eltoprazine Counteracts L-DOPA-induced Dyskinesias in Parkinson's Disease: A Dose-Finding Study," please click here.
To access the Karolinska Institutet press release titled, "New therapeutic principle for Parkinsonian dyskinesia shows clinical effect," regarding the publication in BRAIN, please click here.
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼